These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37388379)

  • 1. Retracted: Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer.
    International BR
    Biomed Res Int; 2023; 2023():9870382. PubMed ID: 37388379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer.
    Xu Y; Shen M; Peng Y; Liu L; Tang L; Yang T; Pu D; Tan W; Zhang W; Liu S
    Biomed Res Int; 2022; 2022():4632453. PubMed ID: 36082153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer.
    Adams MN; Burgess JT; He Y; Gately K; Snell C; Zhang SD; Hooper JD; Richard DJ; O'Byrne KJ
    J Thorac Oncol; 2017 Jul; 12(7):1071-1084. PubMed ID: 28487093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer analysis identifies
    Yang H; Wei X; Zhang L; Xiang L; Wang P
    Transl Cancer Res; 2022 Aug; 11(8):2902-2916. PubMed ID: 36093552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDCA3 Predicts Poor Prognosis and Affects CD8
    Bai Y; Liao S; Yin Z; You B; Lu D; Chen Y; Chen D; Wu Y
    J Oncol; 2022; 2022():6343760. PubMed ID: 36213833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDCA3 Is a Novel Prognostic Biomarker Associated with Immune Infiltration in Hepatocellular Carcinoma.
    Wang Z; Chen S; Wang G; Li S; Qin X
    Biomed Res Int; 2021; 2021():6622437. PubMed ID: 33604380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer.
    Qian W; Zhang Z; Peng W; Li J; Gu Q; Ji D; Wang Q; Zhang Y; Ji B; Wang S; Zhang D; Sun Y
    Int J Oncol; 2018 Nov; 53(5):2021-2033. PubMed ID: 30226575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer.
    Sahin KB; Shah ET; Ferguson GP; Molloy C; Kalita-de Croft P; Hayes SA; Hudson A; Colvin E; Kamitakahara H; Harvie R; Hasovits C; Khan T; Duijf PHG; Howell VM; He Y; Bolderson E; Hooper JD; Lakhani SR; Richard DJ; O'Byrne KJ; Adams MN
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of CDCA3 in kidney renal papillary cell carcinoma.
    Li H; Li M; Yang C; Guo F; Deng S; Li L; Ma T; Yan J; Wu H; Li X
    Aging (Albany NY); 2021 Dec; 13(23):25466-25483. PubMed ID: 34905505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest.
    Uchida F; Uzawa K; Kasamatsu A; Takatori H; Sakamoto Y; Ogawara K; Shiiba M; Tanzawa H; Bukawa H
    BMC Cancer; 2012 Jul; 12():321. PubMed ID: 22839099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDCA3 is a potential prognostic marker that promotes cell proliferation in gastric cancer.
    Zhang Y; Yin W; Cao W; Chen P; Bian L; Ni Q
    Oncol Rep; 2019 Apr; 41(4):2471-2481. PubMed ID: 30816466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy.
    Kildey K; Gandhi NS; Sahin KB; Shah ET; Boittier E; Duijf PHG; Molloy C; Burgess JT; Beard S; Bolderson E; Suraweera A; Richard DJ; O'Byrne KJ; Adams MN
    Commun Biol; 2021 May; 4(1):638. PubMed ID: 34050247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of CDCA3 inhibits prostate cancer progression via NF‑κB/cyclin D1 signaling inactivation and p21 accumulation.
    Gu P; Zhang M; Zhu J; He X; Yang D
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34970697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retracted: IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer.
    Oncology JO
    J Oncol; 2023; 2023():9807856. PubMed ID: 37946722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDCA3 exhibits a role in promoting the progression of ovarian cancer.
    Gong S; Bai B; Sun G; Jin H; Zhang Z
    Tissue Cell; 2022 Dec; 79():101903. PubMed ID: 36081320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retracted: FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma.
    And Biomechanics AB
    Appl Bionics Biomech; 2023; 2023():9798134. PubMed ID: 38075128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncCDCA3L inhibits cell proliferation via a novel RNA structure-based crosstalk with CDCA3 in hepatocellular carcinoma.
    Wang Y; Liu Y; Zhang T; Guan G; Mao T; Liu H; Zhang J; Lu F; Chen X
    Liver Int; 2022 Jun; 42(6):1432-1446. PubMed ID: 35230745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Retracted] KIF4A promotes the development of bladder cancer by transcriptionally activating the expression of CDCA3.
    Zheng P; Wu K; Gao Z; Li H; Li W; Wang X; Shi Z; Xiao F; Wang K; Li Z; Han Q
    Int J Mol Med; 2023 Jul; 52(1):. PubMed ID: 37293853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retracted: HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    International BR
    Biomed Res Int; 2024; 2024():9789013. PubMed ID: 38550155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA hypomethylation promotes invasion and metastasis of gastric cancer cells by regulating the binding of SP1 to the CDCA3 promoter.
    Yu J; Hua R; Zhang Y; Tao R; Wang Q; Ni Q
    J Cell Biochem; 2020 Jan; 121(1):142-151. PubMed ID: 31211445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.